
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Approvals· June 7, 2026 · 8 min read
By Ran Chen#Oncology#PD-L1#Prior Authorization

Pipeline· June 5, 2026 · 11 min read
Atacicept PDUFA preview: first dual BAFF/APRIL therapy approaches IgA nephropathy decision
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence

Pipeline· June 5, 2026 · 12 min read
Gedatolisib PDUFA preview: pan-PI3K/mTOR inhibitor targets HR+/HER2– breast cancer gap
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence

Pipeline· June 3, 2026 · 9 min read
Cendakimab PDUFA preview: IL-13 inhibitor for eosinophilic esophagitis
By Ran Chen#PDUFA Date#FDA Approval#Immunology

Pipeline· June 3, 2026 · 10 min read
NASP PDUFA preview: anti-drug antibody strategy for uncontrolled gout
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence

Pipeline· June 2, 2026 · 10 min read
Orca-T allogeneic cell therapy PDUFA preview: access implications for AML, ALL, and MDS
By Ran Chen#PDUFA Date#FDA Approval#Hematology

Approvals· June 2, 2026 · 9 min read
Xocova (ensitrelvir) access guide: first oral COVID post-exposure prophylaxis

Approvals· June 2, 2026 · 9 min read
Zaynich (cefepime/zidebactam) access guide: novel AMR antibiotic for resistant cUTI

Pipeline· June 1, 2026 · 10 min read
Enhertu early-stage breast cancer: neoadjuvant and adjuvant PA workflow
By Ran Chen#Oncology#FDA Approval#Prior Authorization

Biosimilars· June 1, 2026 · 12 min read
FDA biosimilar interchangeability without switching studies: the 2026 pathway
By Ran Chen#Biosimilars#Interchangeability#FDA Approval